"Discussion on CHAARTED, LATITUDE and... - Advanced Prostate...

Advanced Prostate Cancer

22,014 members27,611 posts

"Discussion on CHAARTED, LATITUDE and STAMPEDE Trials"

pjoshea13 profile image
7 Replies

Not a discussion, but three separate presentations.

Easier to follow for those who are already familiar with the trials & published papers.

-Patrick

urotoday.com/video-lectures...

Written by
pjoshea13 profile image
pjoshea13
To view profiles and participate in discussions please or .
7 Replies
Dan59 profile image
Dan59

Patrick, thank you for this great overview.

Dr_WHO profile image
Dr_WHO

Is there someway we could put this in a special place where it will be available for people to review, not just on this post? It seems like about twice a week there is a post where people would benefit from it.

Thanks. I now know of an oncologist in the Phoenix area.

Flash64 profile image
Flash64

Thanks for this!

rococo profile image
rococo

Excellen% find . will save and review this info. Always a problem when to initiate these new drugs when the studies were for crpc, now hormoe sensitive but the question Iam asking is why xtandi, zytiga , chemo works best for metastatic than none met Why wouldn't earlier on be even better for long term survival? Thanks Patrick.

pjoshea13 profile image
pjoshea13

Rococo,

An excellent question.

Traditionally, it has been easier to do a trial on men who have exhaused all options. The risk to Pharma is that the drug will not work on that population, but might have worked on earlier stage PCa. The advantage of even modest benefit in CRPC is that the FDA will fast track approval. With a foot in the door, Pharma will then try to prove that the drug is useful at earlier stages.

But how do you demonstrate benefit in the short term? With a 5 year trial, one might show that ADT+drug was effective longer than ADT alone (time to biochemical recurrence.) But what about long-lerm survival? What are the characteristics of the cancer after failing ADT+drug versus ADT alone?

Dr. De Bono touched on this in a video I posted yesterday:

onclive.com/peer-exchange/p...

It's an interesting dilemma. My instinct says that when ADT begins, we should block as many escape pathways as we can. That should lead to a more durable therapy. But what happens afterward? Do we have the tools to manage super-resistant PCa?

Ultimately, I believe, there will be up-front drugs that plug the holes that lead to Zytiga/Xtandi resistance.

-Patrick

The point I gather from the Stampede discussion is that docetaxel may be the key drug going forward, as the androgen dependant treatments eventually fail.

Not what you're looking for?

You may also like...

Discussion on Chemo

Finished 39 radiotherapy for tumor growing out of my prostate 5 weeks ago. Been on Degarelix for 3...

What do you want to know about Androgen Deprivation Therapy (ADT, hormone therapy)?

What do you want to know about Androgen Deprivation Therapy (ADT, hormone therapy)? I will record a...

Dr. John Campbell on Vitamin D and Prostate Cancer.

This video from Dr. John Campbell discusses a (in his opinion good) meta-analysis of Vitamin D and...

Interesting PSA progression on STAMPEDE Zytiga (Abiraterone) trial.

Hi All A couple of months ago, I was asked if my PSA results were accurate, as I was quoting from...

Interesting about capsaicin!

I have mentioned a YouTube video several times in which Dr. Klotz shows a chart of a patient's PSA...